Europe meeting, experts discussed the challenges and strategies of small and mid-sized biopharma companies surrounding ...

Pliant Therapeutics will cut 45% of its workforce in a sweeping restructuring effort aimed at extending its cash runway, the ...

BioCardia has announced the enrolment of the first subject in CardiAMP HF II trial of its cell therapy for treating heart ...

AstraZeneca plans to submit the positive data Breztri Aerosphere in asthma for to regulatory authorities for review.

Tempus AI has announced that it is using the TIME Network for Phase I trials to expedite site activation and enrolment.

Data from the NERO study investigating Zejula in mesothelioma was presented at the American Association of Cancer Research ...

Among those consuming UPFs in high-income countries, intake varies significantly across age and socioeconomic status.

Immunic’s drug is currently being investigated in two Phase III trials in patients with relapsing multiple sclerosis.

Neurocrine has commenced a Phase III registrational programme to assess NBI-1117568 as a treatment for schizophrenia in adult ...

Amylyx has dosed the first subject in the Phase III LUCIDITY trial of avexitide for treating post-bariatric hypoglycaemia ...

The London Cancer Hub has been identified as a key district for ‘frontier innovation’ by London Mayor Sadiq Khan.

The FDA approved AstraZeneca's Truqap in November 2023 for the treatment of advanced HR-positive breast cancer.